Related Experiment Video
Updated: Oct 15, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
Development of mRNA vaccines against herpes zoster
Dongdong Li1, Jun Luo1, Junwei Wang1
1Qilu Medical University, Zibo, Shandong, China.
Abstract:
Herpes zoster (HZ), caused by varicella-zoster virus (VZV), remains a substantial public health burden, particularly in aging populations, due to the risk of severe complications like postherpetic neuralgia (PHN). While existing vaccines (eg. Shingrix®) have advanced prevention efficiencies, they present notable limitations, such as high reactogenicity and complex manufacturing. mRNA vaccines represent a transformative alternative with rapid manufacturing, precise antigen design, and favorable safety. This review synthesizes the current landscape of mRNA vaccine development for HZ, focusing on the rational design of antigen constructs, innovations in lipid nanoparticle delivery systems, insights from preclinical immunogenicity studies, and the progress of leading candidates into clinical trials. In summary, this review highlights the potential of mRNA vaccines to address the limitations of current options, potentially offering a new paradigm for safer, highly efficacious, and scalable HZ prevention. Continued clinical validation is crucial to realize this potential and alleviate the global disease burden.
Related Concept Videos
Chickenpox
Genital Herpes
Herpes
Vaccine Production
Respiratory Syncytial Virus Disease
Vaccines

